Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND

Main Article Content

Amy Paller
Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Michael Cork
Sheffield Dermatology Research, IICD, University of Sheffield and Sheffield Children’s Hospital, Sheffield, United Kingdom

Carsten Flohr
St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, London, United Kingdom

Christine Bangert
Medical University of Vienna, Vienna, Austria

Stephan Weidinger
University Hospital Schleswig-Holstein, Kiel, Germany

John Nesnas
Pfizer Ltd., Tadworth, Surrey, United Kingdom;

Saleem Farooqui
Pfizer R & D UK Ltd., Sandwich, Kent, United Kingdom

Pinaki Biswas
Pfizer Inc., New York, NY, USA

Melissa Watkins
Pfizer Inc., New York, NY, USA

Herwig Koppensteiner

Keywords

abrocitinib, adolescents, adults, moderate-to-severe atopic dermatitis, long-term efficacy

References

1. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; February 2023.

2. Cibinqo (abrocitinib) 100 mg film-coated tablets. Summary of product characteristics.
Pfizer Ltd.; March 10, 2023.

3. Simpson EL et al. Lancet. 2020;396:255-266.

4. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.

5. Bieber T et al. N Engl J Med. 2021;384:1101-1112.

6. Eichenfield LF et al. JAMA Dermatol. 2021;157:1165-1173.

Article Sidebar

PDF
Published
Jan 16, 2024
DOI https://doi.org/10.25251/skin.8.supp.329

Article Details

How to Cite
Paller, A., Cork, M., Flohr, C., Bangert, C., Weidinger, S., Nesnas, J., Farooqui, S., Biswas, P., Watkins, M., & Koppensteiner, H. (2024). Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND. SKIN The Journal of Cutaneous Medicine, 8(1), s329. https://doi.org/10.25251/skin.8.supp.329
Issue
Vol. 8 No. 1 (2024): January 2024 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>